Abbott Laboratories $ABT Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 2.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 257,786 shares of the healthcare product maker’s stock after selling 6,450 shares during the period. Yousif Capital Management LLC’s holdings in Abbott Laboratories were worth $35,061,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Lion Street Advisors LLC lifted its stake in Abbott Laboratories by 2.2% during the 2nd quarter. Lion Street Advisors LLC now owns 3,749 shares of the healthcare product maker’s stock valued at $510,000 after acquiring an additional 81 shares during the period. MGO One Seven LLC lifted its stake in Abbott Laboratories by 19.3% during the 2nd quarter. MGO One Seven LLC now owns 25,403 shares of the healthcare product maker’s stock valued at $3,455,000 after acquiring an additional 4,109 shares during the period. Welch Group LLC lifted its stake in Abbott Laboratories by 6.2% during the 2nd quarter. Welch Group LLC now owns 74,915 shares of the healthcare product maker’s stock valued at $10,189,000 after acquiring an additional 4,362 shares during the period. Cypress Capital Group lifted its stake in Abbott Laboratories by 2.2% during the 2nd quarter. Cypress Capital Group now owns 75,820 shares of the healthcare product maker’s stock valued at $10,312,000 after acquiring an additional 1,646 shares during the period. Finally, MOKAN Wealth Management Inc. lifted its stake in Abbott Laboratories by 11.9% during the 2nd quarter. MOKAN Wealth Management Inc. now owns 22,007 shares of the healthcare product maker’s stock valued at $2,993,000 after acquiring an additional 2,347 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. BTIG Research decreased their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Royal Bank Of Canada boosted their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Finally, The Goldman Sachs Group boosted their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $146.17.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $132.30 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a fifty day moving average of $132.54 and a 200 day moving average of $131.60. The firm has a market cap of $230.26 billion, a PE ratio of 16.58, a PEG ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.